Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib vs Prednisone in Mild-to-Moderate SLE
NCT07814664Phase 3Not yet recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Oct 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib in systemic lupus erythematosus (SLE), sponsored by Chinese SLE Treatment And Research Group. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07814664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07814664.